

# SCORE Search Results Details for Application 10552515 and Search Result 20080630\_144055\_us-10-552-515-8.rag.

<a href="#">Score Home</a>	<a href="#">Retrieve Application</a>	<a href="#">SCORE System</a>	<a href="#">SCORE</a>	<a href="#">Comments /</a>
<a href="#">Page</a>	<a href="#">List</a>	<a href="#">Overview</a>	<a href="#">FAQ</a>	<a href="#">Suggestions</a>

This page gives you Search Results detail for the Application 10552515 and Search Result 20080630\_144055\_us-10-552-515-8.rag.

[Go Back to previous page](#)

GenCore version 6.2.1  
Copyright (c) 1993 - 2008 Biocceleration Ltd.

OM protein - protein search, using sw model

Run on: June 30, 2008, 17:43:01 ; Search time 71 Seconds  
(without alignments)  
76.429 Million cell updates/sec

Title: US-10-552-515-8  
Perfect score: 41  
Sequence: 1 ILFEILAKT 9

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 3405708 seqs, 601879884 residues

Total number of hits satisfying chosen parameters: 3405708

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : A\_Geneseq\_200711:\*  
1: geneseqp1980s:\*  
2: geneseqp1990s:\*  
3: geneseqp2000:\*  
4: geneseqp2001:\*  
5: geneseqp2002:\*  
6: geneseqp2003a:\*  
7: geneseqp2003b:\*  
8: geneseqp2004a:\*

9: geneseqp2004b:\*  
 10: geneseqp2005:\*  
 11: geneseqp2006:\*  
 12: geneseqp2007:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	41	100.0	9	8	ADT77671	Adt77671 Splice va
2	41	100.0	843	10	AEB13424	Aeb13424 Human pro
3	41	100.0	885	10	AEB13426	Aeb13426 Human pro
4	41	100.0	898	4	ABG15488	Abg15488 Novel hum
5	41	100.0	933	8	ADT77664	Adt77664 Splice va
6	41	100.0	933	11	AEL84788	Ael84788 Tumor mar
7	34	82.9	216	8	AFP84087	Afp84087 Glycine m
8	33	80.5	1053	8	ADJ34836	Adj34836 Xylanase
9	32	78.0	227	7	ABO63675	Abo63675 Klebsiell
10	32	78.0	241	11	AEH61360	Aeh61360 Enterobac
11	32	78.0	458	6	ABU28956	Abu28956 Protein e
12	32	78.0	458	7	ADL46368	Adl46368 UDP-N-ace
13	32	78.0	458	10	AEC10797	Aec10797 Enterococ
14	32	78.0	461	4	AAU35344	Aau35344 Enterococ
15	32	78.0	463	7	ADH86988	Adh86988 Enterococ
16	32	78.0	463	12	AJF28249	Ajf28249 Enterococ
17	32	78.0	526	4	AAB96073	Aab96073 Putative
18	32	78.0	678	7	ABO71947	Abo71947 Pseudomon
19	32	78.0	1059	8	AFQ00574	Afq00574 Glycine m
20	32	78.0	1076	10	AEN23392	Aen23392 Dugesia j
21	32	78.0	1143	8	AFQ00575	Afq00575 Glycine m
22	31	75.6	151	8	ADT56971	Adt56971 Plant pol
23	31	75.6	166	8	ADK16481	Adk16481 Nanoarcha
24	31	75.6	370	5	ABB90367	Abb90367 Human pol
25	31	75.6	370	7	ADN95748	Adn95748 Human BEC
26	31	75.6	370	8	ADO19268	Ado19268 Human PRO
27	31	75.6	370	8	ADQ19215	Adq19215 Human sof
28	31	75.6	620	8	ADL05423	Adl05423 M. catarr
29	31	75.6	1062	8	ADN19023	Adn19023 Bacterial
30	31	75.6	1102	10	AEN27462	Aen27462 Nostoc pu
31	30	73.2	93	9	AFQ75635	Afq75635 Glycine m
32	30	73.2	239	7	ADF07117	Adf07117 Bacterial
33	30	73.2	292	6	ABU35185	Abu35185 Protein e
34	30	73.2	302	11	AFC64090	Afc64090 Maize ami
35	30	73.2	303	5	ABR52340	Abr52340 Protein r

36	30	73.2	304	8	ADL04486	Adl04486 M. catarr
37	30	73.2	320	11	AFC64089	Afc64089 Maize ami
38	30	73.2	322	5	ABB54400	Abb54400 Lactococc
39	30	73.2	345	10	AEN35225	Aen35225 Zea mays
40	30	73.2	345	11	AFC64088	Afc64088 Maize ami
41	30	73.2	361	9	AFQ22375	Afq22375 Glycine m
42	30	73.2	363	5	ABB91326	Abb91326 Herbicida
43	30	73.2	364	3	AAB18932	Aab18932 Amino aci
44	30	73.2	364	12	AGA87456	Aga87456 Tobacco c
45	30	73.2	365	2	AAR34765	Aar34765 OMTIII tr

## ALIGNMENTS

## RESULT 1

ADT77671

ID ADT77671 standard; peptide; 9 AA.

XX

AC ADT77671;

XX

DT 13-JAN-2005 (first entry)

XX

DE Splice variant-novel gene expressed in prostate (SV-NGEP) epitope.

XX

KW Splice variant-novel gene expressed in prostate; SV-NGEP; human;  
 KW prostate cancer; cytostatic; gene therapy; immunotherapy; epitope.

XX

OS Homo sapiens.

XX

PN WO2004092213-A1.

XX

PD 28-OCT-2004.

XX

PF 05-APR-2004; 2004WO-US010588.

XX

PR 08-APR-2003; 2003US-0461399P.

XX

PA (USSH ) US DEPT HEALTH &amp; HUMAN SERVICES.

XX

PI Pastan I, Bera TK, Lee B;

XX

DR WPI; 2004-758338/74.

XX

PT New Splice Variant-Novel Gene Expressed in Prostate polypeptide or  
 PT encoding nucleic acid molecule for diagnosing, preventing or treating  
 PT cancer, especially prostate cancer.

XX

PS Disclosure; SEQ ID NO 8; 88pp; English.

XX

CC The present sequence is that of a predicted epitope of human splice  
CC variant-novel gene expressed in prostate (SV-NGEP) ADT77664. The epitope  
CC is predicted to bind HLA2-01 and was identified using an HLA binding  
CC motif program. It corresponds to amino acids 258-266 of SV-NGEP.  
CC Polypeptides comprising an immunogenic fragment of 8 consecutive amino  
CC acids of SV-NGEP which specifically bind to an antibody that specifically  
CC binds a polypeptide comprising amino acids 157-933 of SV-NGEP are  
CC claimed. The invention provides methods for: detecting prostate cancer in  
CC a subject by contacting a sample with an antibody that specifically binds  
CC a SV-NGEP polypeptide and detecting the formation of an immune complex,  
CC or detecting an increase in expression of SV-NGEP polypeptide or mRNA;  
CC producing an immune response against a cell expressing SV-NGEP, for  
CC example in a subject with prostate cancer, by administering SV-NGEP  
CC polypeptide or polynucleotide to produce an immune response that  
CC decreases growth of the prostate cancer; inhibiting the growth of a  
CC malignant cell that expresses SV-NGEP by culturing cytotoxic T  
CC lymphocytes (CTLs) with SV-NGEP to produce activated CTLs, and contacting  
CC these with the malignant cell; and inhibiting the growth of a malignant  
CC cell by contact with an antibody that specifically binds SV-NGEP, where  
CC the antibody is linked to a chemotherapeutic agent or toxin.

XX

SQ Sequence 9 AA;

Query Match	100.0%;	Score 41;	DB 8;	Length 9;
Best Local Similarity	100.0%;	Pred. No. 2.9e+06;		
Matches	9;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;

Qy 1 ILFEILAKT 9  
| | | | | | | | |  
Db 1 ILFEILAKT 9

RESULT 2

AEB13424

ID AEB13424 standard; protein; 843 AA.

XX

AC AEB13424;

XX

DT 22-SEP-2005 (first entry)

XX

DE Human prostate specific polypeptide #1.

XX

KW Screening; diagnosis; drug delivery; prostate specific polypeptide;  
KW cancer; prostate tumor; cytostatic; neoplasm.

XX

OS Homo sapiens.

XX

PN W02005062788-A2.

XX  
PD 14-JUL-2005.  
XX  
PF 16-DEC-2004; 2004WO-US042406.  
XX  
PR 22-DEC-2003; 2003US-0531809P.  
XX  
PA (AVAL-) AVALON PHARM INC.  
XX  
PI Weigle B, Ebner R;  
XX  
DR WPI; 2005-497793/50.  
DR N-PSDB; AEB13423.  
XX  
PT Novel isolated prostate specific polypeptide, useful for treating cancer,  
PT and identifying agent that modulates activity of cancer related gene.  
XX  
PS Claim 12; SEQ ID NO 3; 59pp; English.  
XX  
CC The invention relates to an isolated prostate specific polypeptide  
CC comprising one or more immunogenic fragments. The invention also relates  
CC to a method of identifying an agent that modulates the activity of a  
CC cancer related gene involving contacting a compound with a cell  
CC containing a gene under conditions promoting the expression of the gene,  
CC detecting a difference in expression of the gene relative to when the  
CC compound is not present and identifying an agent that modulates the  
CC activity of a cancer related gene, a method of identifying an anti-  
CC neoplastic agent involving contacting a cell exhibiting neoplastic  
CC activity with a compound first identified as a cancer related gene  
CC modulator using and determining a decrease in neoplastic activity after  
CC contacting, when compared to when the contacting does not occur, or  
CC administering an agent first identified to an animal exhibiting a cancer  
CC condition and detecting a decrease in cancerous condition, a method of  
CC determining the cancerous status of a cell involving determining an  
CC increase in the level of expression in a cell of a gene where an elevated  
CC expression relative to a known non-cancerous cell indicates a cancerous  
CC state or potentially cancerous state, an antibody that reacts with a  
CC prostate specific polypeptide, an immunoconjugate comprising the antibody  
CC and a cytotoxic agent, a method of treating cancer involving contacting a  
CC cancerous cell in vivo with an agent having activity against a prostate  
CC specific polypeptide and an immunogenic composition the prostate specific  
CC polypeptide. The prostate specific polypeptide is useful for identifying  
CC an agent that modulates the activity of a cancer related gene. The  
CC immunogenic composition is useful for treating cancer, preferably  
CC prostate cancer in an animal, e.g. human, which involves administering  
CC the immunogenic composition that is sufficient to elicit the production  
CC of cytotoxic T lymphocytes specific for the prostate specific  
CC polypeptide. The invention is useful for identifying anti-neoplastic  
CC agents. This sequence represents a human prostate specific polypeptide of

CC the invention.  
XX  
SQ Sequence 843 AA;  
  
Query Match 100.0%; Score 41; DB 10; Length 843;  
Best Local Similarity 100.0%; Pred. No. 13;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ILFEILAKT 9  
|||  
Db 259 ILFEILAKT 267

RESULT 3  
AEB13426  
ID AEB13426 standard; protein; 885 AA.  
XX  
AC AEB13426;  
XX  
DT 22-SEP-2005 (first entry)  
XX  
DE Human prostate specific polypeptide #2.  
XX  
KW Screening; diagnosis; drug delivery; prostate specific polypeptide;  
KW cancer; prostate tumor; cytostatic; neoplasm.  
XX  
OS Homo sapiens.  
XX  
PN WO2005062788-A2.  
XX  
PD 14-JUL-2005.  
XX  
PF 16-DEC-2004; 2004WO-US042406.  
XX  
PR 22-DEC-2003; 2003US-0531809P.  
XX  
PA (AVAL-) AVALON PHARM INC.  
XX  
PI Weigle B, Ebner R;  
XX  
DR WPI; 2005-497793/50.  
DR N-PSDB; AEB13425.  
XX  
PT Novel isolated prostate specific polypeptide, useful for treating cancer,  
PT and identifying agent that modulates activity of cancer related gene.  
XX  
PS Claim 12; SEQ ID NO 5; 59pp; English.  
XX  
CC The invention relates to an isolated prostate specific polypeptide

comprising one or more immunogenic fragments. The invention also relates to a method of identifying an agent that modulates the activity of a cancer related gene involving contacting a compound with a cell containing a gene under conditions promoting the expression of the gene, detecting a difference in expression of the gene relative to when the compound is not present and identifying an agent that modulates the activity of a cancer related gene, a method of identifying an anti-neoplastic agent involving contacting a cell exhibiting neoplastic activity with a compound first identified as a cancer related gene modulator using and determining a decrease in neoplastic activity after contacting, when compared to when the contacting does not occur, or administering an agent first identified to an animal exhibiting a cancer condition and detecting a decrease in cancerous condition, a method of determining the cancerous status of a cell involving determining an increase in the level of expression in a cell of a gene where an elevated expression relative to a known non-cancerous cell indicates a cancerous state or potentially cancerous state, an antibody that reacts with a prostate specific polypeptide, an immunoconjugate comprising the antibody and a cytotoxic agent, a method of treating cancer involving contacting a cancerous cell in vivo with an agent having activity against a prostate specific polypeptide and an immunogenic composition the prostate specific polypeptide. The prostate specific polypeptide is useful for identifying an agent that modulates the activity of a cancer related gene. The immunogenic composition is useful for treating cancer, preferably prostate cancer in an animal, e.g. human, which involves administering the immunogenic composition that is sufficient to elicit the production of cytotoxic T lymphocytes specific for the prostate specific polypeptide. The invention is useful for identifying anti-neoplastic agents. This sequence represents a human prostate specific polypeptide of the invention.

XX

SQ Sequence 885 AA;

Query Match 100.0%; Score 41; DB 10; Length 885;  
Best Local Similarity 100.0%; Pred. No. 14;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ILFEILAKT 9  
| | | | | | | |  
Db 259 ILFEILAKT 267

RESULT 4

ABG15488

ID ABG15488 standard; protein; 898 AA.

XX

AC ABG15488;

XX

DT 18-FEB-2002 (first entry)

XX  
DE Novel human diagnostic protein #15479.  
XX  
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;  
KW food supplement; medical imaging; diagnostic; genetic disorder.  
XX  
OS Homo sapiens.  
XX  
PN WO200175067-A2.  
XX  
PD 11-OCT-2001.  
XX  
PF 30-MAR-2001; 2001WO-US008631.  
XX  
PR 31-MAR-2000; 2000US-00540217.  
PR 23-AUG-2000; 2000US-00649167.  
XX  
PA (HYSE-) HYSEQ INC.  
XX  
PI Drmanac RT, Liu C, Tang YT;  
XX  
DR WPI; 2001-639362/73.  
DR N-PSDB; AAS79675.  
XX  
PT New isolated polynucleotide and encoded polypeptides, useful in  
PT diagnostics, forensics, gene mapping, identification of mutations  
PT responsible for genetic disorders or other traits and to assess  
PT biodiversity.  
XX  
PS Claim 20; SEQ ID NO 45847; 103pp; English.  
XX  
CC The invention relates to isolated polynucleotide (I) and polypeptide (II)  
CC sequences. (I) is useful as hybridisation probes, polymerase chain  
CC reaction (PCR) primers, oligomers, and for chromosome and gene mapping,  
CC and in recombinant production of (II). The polynucleotides are also used  
CC in diagnostics as expressed sequence tags for identifying expressed  
CC genes. (I) is useful in gene therapy techniques to restore normal  
CC activity of (II) or to treat disease states involving (II). (II) is  
CC useful for generating antibodies against it, detecting or quantitating a  
CC polypeptide in tissue, as molecular weight markers and as a food  
CC supplement. (II) and its binding partners are useful in medical imaging  
CC of sites expressing (II). (I) and (II) are useful for treating disorders  
CC involving aberrant protein expression or biological activity. The  
CC polypeptide and polynucleotide sequences have applications in  
CC diagnostics, forensics, gene mapping, identification of mutations  
CC responsible for genetic disorders or other traits to assess biodiversity  
CC and to produce other types of data and products dependent on DNA and  
CC amino acid sequences. ABG00010-ABG30377 represent novel human diagnostic  
CC amino acid sequences of the invention. Note: The sequence data for this

CC patent did not appear in the printed specification, but was obtained in  
CC electronic format directly from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 898 AA;

Query Match 100.0%; Score 41; DB 4; Length 898;  
Best Local Similarity 100.0%; Pred. No. 14;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ILFEILAKT 9  
| | | | | | | |  
Db 351 ILFEILAKT 359

RESULT 5  
ADT77664

ID ADT77664 standard; protein; 933 AA.  
XX  
AC ADT77664;  
XX  
DT 15-JUN-2007 (revised)  
DT 13-JAN-2005 (first entry)  
XX  
DE Splice variant-novel gene expressed in prostate (SV-NGEP) polypeptide.  
XX  
KW Splice variant-novel gene expressed in prostate; SV-NGEP; human;  
KW prostate cancer; cytostatic; gene therapy; immunotherapy; BOND\_PC;  
KW NGEP long variant; NGEP long variant [Homo sapiens]; G05886.  
XX  
OS Homo sapiens.  
XX  
FH Key Location/Qualifiers  
FT Domain 1. .345  
FT /label= Cytoplasmic  
FT Region 157. .933  
FT /note= "An immunogenic fragment comprising 8 consecutive  
FT amino acids that specifically binds to an antibody that  
FT specifixally binds to a polypeptide comprising amino  
FT acids 157-933 is referred to in Claim 1"  
FT Region 170. .178  
FT /note= "Epitope, predicted to bind HLA2-01"  
FT Region 215. .223  
FT /note= "Epitope, predicted to bind HLA2-01"  
FT Region 258. .266  
FT /note= "Epitope, predicted to bind HLA2-01"  
FT Domain 346. .368  
FT /label= Transmembrane  
FT Domain 369. .421

FT		/label= External
FT		/note= "Cell surface"
FT	Region	403. .411
FT		/note= "Epitope, predicted to bind HLA2-01"
FT	Domain	422. .441
FT		/label= Transmembrane
FT	Region	427. .435
FT		/note= "Epitope, predicted to bind HLA2-01"
FT	Domain	442. .501
FT		/label= Cytoplasmic
FT	Domain	502. .524
FT		/label= Transmembrane
FT	Domain	525. .543
FT		/label= External
FT		/note= "Cell surface"
FT	Domain	544. .566
FT		/label= Transmembrane
FT	Region	557. .565
FT		/note= "Epitope, predicted to bind HLA2-01"
FT	Region	562. .570
FT		/note= "Epitope, predicted to bind HLA2-01"
FT	Domain	567. .586
FT		/label= Cytoplasmic
FT	Domain	587. .609
FT		/label= Transmembrane
FT	Domain	610. .714
FT		/label= External
FT		/note= "Cell surface"
FT	Domain	715. .737
FT		/label= Transmembrane
FT	Domain	738. .761
FT		/label= Cytoplasmic
FT	Domain	762. .784
FT		/label= Transmembrane
FT	Domain	785. .933
FT		/label= External
FT		/note= "Cell surface"
FT	Region	846. .854
FT		/note= "Epitope, predicted to bind HLA2-01"
XX		
PN	WO2004092213-A1.	
XX		
PD	28-OCT-2004.	
XX		
PF	05-APR-2004; 2004WO-US010588.	
XX		
PR	08-APR-2003; 2003US-0461399P.	
XX		
PA	(USSH ) US DEPT HEALTH & HUMAN SERVICES.	

XX

PI Pastan I, Bera TK, Lee B;

XX

DR WPI; 2004-758338/74.

DR N-PSDB; ADT77665.

DR PC:NCBI; gi48093524.

XX

PT New Splice Variant–Novel Gene Expressed in Prostate polypeptide or  
PT encoding nucleic acid molecule for diagnosing, preventing or treating  
PT cancer, especially prostate cancer.

XX

PS Claim 1; SEQ ID NO 1; 88pp; English.

XX

CC The present sequence is the protein sequence of splice variant–novel gene  
CC expressed in prostate (SV-NGEP). SV-NGEP is identical to NGEP from amino  
CC acid 1–157, diverging from amino acid 158. Expression analysis in 76  
CC normal and foetal tissues showed SV-NGEP to be strongly expressed only in  
CC a prostate sample. Claimed methods for detecting prostate cancer in a  
CC subject comprise: contacting the sample with an antibody that  
CC specifically binds a SV-NGEP polypeptide and detecting the formation of  
CC an immune complex; or detecting an increase in expression of SV-NGEP  
CC polypeptide or mRNA. Antibodies to an SV-NGEP polypeptide can be used to  
CC detect metastatic prostate cancer cells at locations other than the  
CC prostate. A claimed method for producing an immune response against a  
CC cell expressing SV-NGEP, for example in a subject with prostate cancer,  
CC comprises administering the polypeptide, or a polynucleotide encoding it,  
CC to produce an immune response that decreases growth of the prostate  
CC cancer. A claimed method for inhibiting the growth of a malignant cell  
CC that expresses SV-NGEP comprises culturing cytotoxic T lymphocytes (CTLs)  
CC with SV-NGEP to produce activated CTLs that recognise an NGEP expressing  
CC cell, and contacting the malignant cell with the activated CTLs.  
CC Alternatively, growth of a malignant cell is inhibited by contact with an  
CC antibody that specifically binds an SV-NGEP polypeptide, where the  
CC antibody is linked to an effector molecule (chemotherapeutic agent or  
CC toxin) that inhibits growth of the malignant cell. This may be performed  
CC in vivo. Kits for detecting an SV-NGEP polypeptide or polynucleotide in a  
CC sample are also claimed.

CC

CC Revised record issued on 15-JUN-2007 : Enhanced with precomputed  
CC information from BOND.

XX

SQ Sequence 933 AA;

Query Match 100.0%; Score 41; DB 8; Length 933;

Best Local Similarity 100.0%; Pred. No. 14;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ILFEILAKT 9

|||||||

Db 258 ILFEILAKT 266

## RESULT 6

AEL84788

ID AEL84788 standard; protein; 933 AA.

XX

AC AEL84788;

XX

DT 18-OCT-2007 (revised)

DT 15-JUN-2007 (revised)

DT 28-DEC-2006 (first entry)

XX

DE Tumor marker gene NGEP SEQ ID NO 155.

XX

KW cytostatic; diagnosis; prognosis; tumor marker; gene expression;

KW drug screening; cancer; neoplasm; NGEP; BOND\_PC; NGEP long variant;

KW GO5886.

XX

OS Homo sapiens.

XX

PN WO2006110593-A2.

XX

PD 19-OCT-2006.

XX

PF 07-APR-2006; 2006WO-US013172.

XX

PR 07-APR-2005; 2005US-0669342P.

PR 11-OCT-2005; 2005US-0725982P.

XX

PA (MACR-) MACROGENICS INC.

XX

PI Von Haller PD, Schummer M, Meyer DW, Schubert LA, Tjoelker LW;

XX

DR WPI; 2006-814687/82.

DR N-PSDB; AEL84787.

DR REFSEQ; NP\_001001891.

DR PC:NCBI; gi48093524.

XX

PT Detecting or diagnosing cancer in a subject comprises determining  
PT expression of at least one gene, and comparing level of expression to a  
PT control sample from a normal subject, where increased expression level  
PT indicates cancer.

XX

PS Claim 8; SEQ ID NO 155; 583pp; English.

XX

CC The invention describes a method of detecting or diagnosing cancer in a  
CC subject comprising determining the expression level of at least one gene,  
CC and comparing the level of expression to a corresponding control sample

from a normal subject, where cancer is detected or diagnosed if there is an increase in the expression level of the gene relative to the expression in the control sample. Also described are: identifying a compound to be tested for its ability to prevent, treat, manage, or ameliorate cancer or its symptom; a compound identified by the method; treating cancer in a patient; treating a cancer in a subject that is fully or partially refractory to a first treatment in a patient; and a pharmaceutical composition comprising an amount of an antibody selected from anti-SLC12A2, anti-FLJ23375, anti-GRM5, anti-TAS2R1, anti-NRXN2, anti-C14orf160, anti-MGC 15668, anti-MGC33486, anti-TMEM16F, anti-FAT, anti-KIAA0195, anti-LRFN, anti-NFASC, anti-BAT2D1, anti-MGC2963, anti-KIAA0685, anti-EDG3, anti-GGTL3, anti-PLVAP, anti-FLJ31528, anti-FLJ90709, anti-VEZATIN, anti-TMPRSS9, anti-ATP13A5, anti-PKHD1L1, anti-C2orf18, anti-ANKRD22, anti-FAM62B, anti-LOC57168, anti-CDKAL1, anti-SLC39A3v1, anti-SLC39A3v2, anti-BAT5, anti-TM9SF4, anti-DC2, anti-VAPB, anti-XTP3TPB, anti-TACSTD2, anti-FNDC3A, anti-GK001, anti-OCIAD2, anti-PR01855, anti-C20orf3, anti-SDFR1, anti-FLJ20481, anti-LENG4, anti-FLJ12443, anti-ARP5 Long, anti-ARP5 Short, anti-TMD0645, anti-NGEP, anti-IL1RAP1, anti-PLXNB1, anti-ATP2B2, anti-FLJ11848, anti-ENTPD2, anti-PPM1H, anti-KRTKAP3, anti-KCNC3, anti-TM9SF1, anti-ULBP1, anti-C19orf26, anti-KIAA830, anti-KIAA1244, anti-KIAA1797, anti-MGC26856, anti-NETO2, anti-SUSD2, anti-FOLR2, anti-EMR2, ENTPD1, anti-ATP10B, anti-PTK7, anti-FLJ14681, anti-C20orf22, anti-FLJ14281, anti-FAM8A1, anti-TMED7, anti-C20orf108, anti-ATAD1, anti-GPR154, anti-C14orf27, anti-OSAP, anti-FAD104, anti-FLJ90492, anti-SLC27A3, anti-RON, anti-ATP13A1, anti-DKFZP564D166, anti-ESSPL, anti-EXTL3, anti-KAI1, anti-KIAA0960, anti-MTRNL, anti-SLC27A1, anti-GRIA, anti-OR4M1, anti-KIAA1679, or anti-UPK-1b antibody, and a pharmaceutical carrier. The methods are useful for detecting, diagnosing, and treating cancer, e.g. colon, lung, ovary, prostate, pancreas, or bladder cancer. This is the amino acid sequence of NGEP, altered levels of expression are useful in the diagnosis or prognosis of cancer.

Revised record issued on 18-OCT-2007 : Enhanced with precomputed information from BOND.

XX

SQ Sequence 933 AA;

Query Match	100.0%;	Score 41;	DB 11;	Length 933;
Best Local Similarity	100.0%;	Pred. No. 14;		
Matches	9;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;

Qy	1	ILFEILAKT	9
Db	258	ILFEILAKT	266

RESULT 7  
AFP84087

ID AFP84087 standard; protein; 216 AA.  
 XX  
 AC AFP84087;  
 XX  
 DT 18-OCT-2007 (first entry)  
 XX  
 DE Glycine max protein SEQ ID NO:175265.  
 XX  
 KW plant; cold tolerance; heat tolerance; drought resistance;  
 KW herbicide resistance; pathogen resistance; pesticide resistance;  
 KW disease-resistance; crop improvement; insect resistance;  
 KW nitrogen fixation; plant growth regulation; plant disease;  
 KW stress tolerance; seed oil; transgenic.  
 XX  
 OS Glycine max.  
 XX  
 PN US2004031072-A1.  
 XX  
 PD 12-FEB-2004.  
 XX  
 PF 28-APR-2003; 2003US-00424599.  
 XX  
 PR 06-MAY-1999; 99US-00304517.  
 PR 05-NOV-2001; 2001US-00985678.  
 XX  
 PA (LROS/) LA ROSA T J.  
 PA (ZHOU/) ZHOU Y.  
 PA (KOVA/) KOVALIC D K.  
 PA (CAOY/) CAO Y.  
 XX  
 PI La Rosa TJ, Zhou Y, Kovalic DK, Cao Y;  
 XX  
 DR WPI; 2004-168999/16.  
 XX  
 PT New recombinant DNA construct, useful in producing plants with desired  
 PT properties, e.g. increased cold, heat or drought tolerance or tolerance  
 PT to herbicides, extreme osmotic conditions or pathogens and improved plant  
 PT growth and development.  
 XX  
 PS Claim 2; SEQ ID NO 175265; 15pp; English.  
 XX  
 CC The invention relates to a recombinant DNA construct, polynucleotides or  
 CC polypeptides which are useful in improving plant cold, heat or drought  
 CC tolerance or tolerance to herbicides, extreme osmotic conditions,  
 CC pathogens or pests, in improving yield by modification of photosynthesis  
 CC or of carbohydrate, nitrogen or phosphorus use and/or uptake, in  
 CC manipulating growth rate in plant cells by modification of the cell cycle  
 CC pathway, in providing increased resistance to plant disease and improved  
 CC plant growth and development under at least one stress condition, in

CC producing galactomannan, plant growth regulators and lignin, in  
CC increasing the rate of homologous recombination in plants, in modifying  
CC seed oil yield and/or content and seed protein yield and/or content and  
CC in encoding a plant transcription factor. The present sequence represents  
CC a Glycine max protein of the invention. Note: This sequence is not shown  
CC in the specification but was obtained in electronic format directly from  
CC USPTO at seqdata.uspto.gov/sequence.html.

XX

SQ Sequence 216 AA;

Query Match 82.9%; Score 34; DB 8; Length 216;  
Best Local Similarity 87.5%; Pred. No. 90;  
Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ILFEILAK 8  
||||:||||  
Db 129 ILFELLAK 136

RESULT 8

ADJ34836

ID ADJ34836 standard; protein; 1053 AA.

XX

AC ADJ34836;

XX

DT 22-APR-2004 (first entry)

XX

DE Xylanase from an environmental sample seq id 52.

XX

KW antibacterial; fungicide; thermostable xylanase activity;  
KW dough conditioning; beverage production; nutritional supplement;  
KW animal feed; lignin reduction; wood product; xylan; bacterial infection;  
KW fungal infection; coccidiosis.

XX

OS Unidentified.

XX

PN WO2003106654-A2.

XX

PD 24-DEC-2003.

XX

PF 16-JUN-2003; 2003WO-US019153.

XX

PR 14-JUN-2002; 2002US-0389299P.

XX

PA (DIVE-) DIVERSA CORP.

XX

PI Steer B, Callen W, Healey S, Hazlewood G, Wu D, Blum D;  
PI Esteghlalian A;

XX

DR WPI; 2004-099016/10.  
DR N-PSDB; ADJ34835.  
XX  
PT Novel xylanase recombinant polypeptide useful for improving textile  
PT texture, treating paper, eliminating microorganisms.  
XX  
PS Claim 60; SEQ ID NO 52; 570pp; English.  
XX  
CC The invention describes an isolated or recombinant polypeptide (I),  
CC having 50% or more identity to 190 300-1200 residue amino acid sequences  
CC (S1), given in the specification, over a region of 100 or more residues  
CC and the polypeptide as thermostable xylanase activity. (I) is useful for:  
CC dough conditioning; beverage production; as a nutritional supplement in  
CC animal feed; reducing lignin in a wood or a wood product; and for  
CC eliminating and protecting animals from a microorganism comprising xylan.  
CC The polynucleotide (II) encoding (I) is useful for amplifying nucleic  
CC acid encoding a polypeptide having a xylanase activity which involves  
CC amplification of a template nucleic acid with a primer pair capable of  
CC amplifying (II) or its subsequence. (I) is useful for treating and  
CC preventing bacterial infection and fungal infection e.g. coccidiosis.  
CC This is the amino acid sequence of a xylanase protein isolated from an  
CC environmental sample.  
XX  
SQ Sequence 1053 AA;

Query Match 80.5%; Score 33; DB 8; Length 1053;  
Best Local Similarity 75.0%; Pred. No. 8.1e+02;  
Matches 6; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 2 LFEILAKT 9  
|||:|:|  
Db 124 LFEVLART 131

RESULT 9  
ABO63675  
ID ABO63675 standard; protein; 227 AA.  
XX  
AC ABO63675;  
XX  
DT 29-JUL-2004 (first entry)  
XX  
DE Klebsiella pneumoniae polypeptide seqid 10192.  
XX  
KW Recombinant expression vector; transcription regulatory element;  
KW Klebsiella pneumoniae protein; antibacterial; Vaccine.  
XX  
OS Klebsiella pneumoniae.  
XX

PN US6610836-B1.  
XX  
PD 26-AUG-2003.  
XX  
PF 27-JAN-2000; 2000US-00489039.  
XX  
PR 29-JAN-1999; 99US-0117747P.  
XX  
PA (GENO-) GENOME THERAPEUTICS CORP.  
XX  
PI Breton GL, Osborne M;  
XX  
DR WPI; 2003-895346/82.  
DR N-PSDB; ACH97226.  
XX  
PT New nucleic acid encoding a Klebsiella pneumoniae polypeptide, useful for  
PT preparing a vaccine composition against Klebsiella pneumoniae.  
XX  
PS Disclosure; SEQ ID NO 10192; 932pp; English.  
XX  
CC The invention describes a new isolated nucleic acid encoding a Klebsiella  
CC pneumoniae polypeptide. Also described are: a recombinant expression  
CC vector comprising the nucleic acid, operably linked to a transcription  
CC regulatory element; and a cell comprising the recombinant expression  
CC vector. The nucleic acid is useful for preparing a vaccine composition  
CC against Klebsiella pneumoniae. This is the amino acid sequence of a  
CC Klebsiella pneumoniae polypeptide of the invention  
XX  
SQ Sequence 227 AA;

Query Match 78.0%; Score 32; DB 7; Length 227;  
Best Local Similarity 87.5%; Pred. No. 2.5e+02;  
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 LFEILAKT 9  
|| |||||  
Db 58 LFSILAKT 65

RESULT 10  
AEH61360  
ID AEH61360 standard; protein; 241 AA.  
XX  
AC AEH61360;  
XX  
DT 13-JUL-2006 (first entry)  
XX  
DE Enterobacter cloacae protein amino acid sequence - SEQ ID 7797.  
XX

KW diagnosis; vaccine; bacterial infection; enterobacter infection;  
KW antibacterial; screening.  
XX  
OS Enterobacter cloacae.  
XX  
PN US7041814-B1.  
XX  
PD 09-MAY-2006.  
XX  
PF 18-FEB-1999; 99US-00252691.  
XX  
PR 18-FEB-1998; 98US-0074787P.  
PR 24-JUL-1998; 98US-0094145P.  
XX  
PA (GENO-) GENOME THERAPEUTICS CORP.  
XX  
PI Weinstock KG, Deloughery C, Bush D;  
XX  
DR WPI; 2006-349670/36.  
DR N-PSDB; AEH53965.  
XX  
PT New nucleic acid encoding an Enterobacter cloacae polypeptide, useful for  
PT detecting, preventing, and treating pathological conditions resulting  
PT from bacterial infections.  
XX  
PS Disclosure; SEQ ID NO 7797; 165pp; English.  
XX  
CC The invention comprises the amino acid and coding sequences of  
CC Enterobacter cloacae proteins. The DNA and protein sequences of the  
CC invention are useful for detecting, preventing, and treating pathological  
CC conditions resulting from bacterial infections, and as components of  
CC antibacterial vaccines. The DNA and protein sequences of the invention  
CC are also useful in screening for compounds which interfere with the  
CC Enterobacter cloacae life cycle or inhibit infection. The present amino  
CC acid sequence represents an Enterobacter cloacae protein of the  
CC invention.  
XX  
SQ Sequence 241 AA;

Query Match 78.0%; Score 32; DB 11; Length 241;  
Best Local Similarity 87.5%; Pred. No. 2.7e+02;  
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 LFEILAKT 9  
|| |||||  
Db 72 LFSILAKT 79

RESULT 11

ABU28956

ID ABU28956 standard; protein; 458 AA.

XX

AC ABU28956;

XX

DT 15-JUN-2007 (revised)

DT 19-JUN-2003 (first entry)

XX

DE Protein encoded by Prokaryotic essential gene #14483.

XX

KW Antisense; prokaryotic essential gene; cell proliferation; drug design;

KW BOND\_PC; UDP-N-acetylglucosamine pyrophosphorylase;

KW UDP-N-acetylglucosamine pyrophosphorylase [Enterococcus faecalis V583];

KW glmU.

XX

OS Enterococcus faecalis.

XX

PN WO200277183-A2.

XX

PD 03-OCT-2002.

XX

PF 21-MAR-2002; 2002WO-US009107.

XX

PR 21-MAR-2001; 2001US-00815242.

PR 06-SEP-2001; 2001US-00948993.

PR 25-OCT-2001; 2001US-0342923P.

PR 08-FEB-2002; 2002US-00072851.

PR 06-MAR-2002; 2002US-0362699P.

XX

PA (ELIT-) ELITRA PHARM INC.

XX

PI Wang L, Zamudio C, Malone C, Haselbeck R, Ohlsen KL, Zyskind JW;

PI Wall D, Trawick JD, Carr GJ, Yamamoto R, Forsyth RA, Xu HH;

XX

DR WPI; 2003-029926/02.

DR N-PSDB; ACA32826.

DR PC:NCBI; gi29342175.

DR PC:SWISSPROT; Q839U1.

XX

PT New antisense nucleic acids, useful for identifying proteins or screening

PT for homologous nucleic acids required for cellular proliferation to

PT isolate candidate molecules for rational drug discovery programs.

XX

PS Claim 25; SEQ ID NO 56880; 1766pp; English.

XX

CC The invention relates to an isolated nucleic acid comprising any one of  
CC the 6213 antisense sequences given in the specification where expression  
CC of the nucleic acid inhibits proliferation of a cell. Also included are:

CC (1) a vector comprising a promoter operably linked to the nucleic acid

CC encoding a polypeptide whose expression is inhibited by the antisense  
CC nucleic acid; (2) a host cell containing the vector; (3) an isolated  
CC polypeptide or its fragment whose expression is inhibited by the  
CC antisense nucleic acid; (4) an antibody capable of specifically binding  
CC the polypeptide; (5) producing the polypeptide; (6) inhibiting cellular  
CC proliferation or the activity of a gene in an operon required for  
CC proliferation; (7) identifying a compound that influences the activity of  
CC the gene product or that has an activity against a biological pathway  
CC required for proliferation, or that inhibits cellular proliferation; (8)  
CC identifying a gene required for cellular proliferation or the biological  
CC pathway in which a proliferation-required gene or its gene product lies  
CC or a gene on which the test compound that inhibits proliferation of an  
CC organism acts; (9) manufacturing an antibiotic; (10) profiling a  
CC compound's activity; (11) a culture comprising strains in which the gene  
CC product is overexpressed or underexpressed; (12) determining the extent  
CC to which each of the strains is present in a culture or collection of  
CC strains; or (13) identifying the target of a compound that inhibits the  
CC proliferation of an organism. The antisense nucleic acids are useful for  
CC identifying proteins or screening for homologous nucleic acids required  
CC for cellular proliferation to isolate candidate molecules for rational  
CC drug discovery programs, or for screening homologous nucleic acids  
CC required for proliferation in cells other than *S. aureus*, *S. typhimurium*,  
CC *K. pneumoniae* or *P. aeruginosa*. The present sequence is encoded by one of  
CC the target prokaryotic essential genes. Note: The sequence data for this  
CC patent did not form part of the printed specification, but was obtained  
CC in electronic format directly from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
CC

CC Revised record issued on 15-JUN-2007 : Enhanced with precomputed  
CC information from BOND.

XX

SQ Sequence 458 AA;

Query Match 78.0%; Score 32; DB 6; Length 458;  
Best Local Similarity 87.5%; Pred. No. 5.4e+02;  
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 LFEILAKT 9  
||| ||||  
Db 181 LFEALAKT 188

RESULT 12

ADL46368

ID ADL46368 standard; protein; 458 AA.

XX

AC ADL46368;

XX

DT 20-MAY-2004 (first entry)

XX  
DE UDP-N-acetylpyruvoylglucosamine reductase protein #1.  
XX  
KW antibacterial; UDP-N-acetylglucosamine 1-carboxyvinyl transferase-1;  
KW CTP:CMP-3-deoxy-D-manno-octulosonate transferase;  
KW UDP-N-acetylmuramylalanyl-D-glutamate-2-6-diaminopimelate ligase;  
KW D-alanine-D-alanine adding enzyme; D-alanine-D-alanine ligase;  
KW UDP-N-acetylpyruvoylglucosamine reductase;  
KW UDP-N-acetylglucosamine pyrophosphorylase;  
KW UDP-N-acetylmuramoylalanine-D-glutamate ligase;  
KW DP-N-acetylmuramate:alanine ligase; aspartate semialdehyde dehydrogenase;  
KW UDP-N-acetylmuramoylalanyl-D-glutamate; X-ray diffraction analysis;  
KW enzyme.  
XX  
OS Pseudomonas aeruginosa.  
XX  
PN WO2003087353-A2.  
XX  
PD 23-OCT-2003.  
XX  
PF 08-APR-2003; 2003WO-CA000481.  
XX  
PR 08-APR-2002; 2002US-0370899P.  
PR 08-APR-2002; 2002US-0370915P.  
PR 09-APR-2002; 2002US-0371107P.  
PR 09-APR-2002; 2002US-0371185P.  
PR 31-MAY-2002; 2002US-0385426P.  
PR 06-JUN-2002; 2002US-0386283P.  
PR 01-AUG-2002; 2002US-0400348P.  
PR 06-NOV-2002; 2002US-0424395P.  
PR 08-NOV-2002; 2002US-0425200P.  
PR 24-DEC-2002; 2002US-0436345P.  
PR 24-DEC-2002; 2002US-0436349P.  
PR 26-DEC-2002; 2002US-0436568P.  
PR 27-DEC-2002; 2002US-0436675P.  
PR 27-DEC-2002; 2002US-0436734P.  
PR 27-DEC-2002; 2002US-0436885P.  
PR 27-DEC-2002; 2002US-0436889P.  
PR 27-DEC-2002; 2002US-0436893P.  
PR 27-DEC-2002; 2002US-0436900P.  
PR 30-DEC-2002; 2002US-0437013P.  
XX  
PA (AFFI-) AFFINIUM PHARM INC.  
XX  
PI Edwards A, Dharamsi A, Vedadi M, Domagala M, Houston S, Awrey D;  
PI Beattie B, Mansoury K, Ouyang H, Vallee F, Richards D, Nethery K;  
PI Virag C, Buzadzija K, Pinder B, Alam MZ, Tai M, Canadien V;  
PI Kanagarajah D, Thalakada R;  
XX

DR WPI; 2003-865361/80.  
DR N-PSDB; ADL46367.  
XX  
PT New recombinant bacterial enzymes involved in cell membrane biogenesis,  
PT useful for designing potential antibacterial agents.  
XX  
PS Claim 245; SEQ ID NO 86; 407pp; English.  
XX  
CC The invention relates to isolated, recombinant polypeptides (I) that have  
CC at least one activity of specified bacterial enzymes involved in cell  
CC membrane biogenesis. (I) are: UDP-N-acetylglucosamine 1-carboxyvinyl  
CC transferase-1 of Streptococcus pneumoniae (S.p), Pseudomonas aeruginosa  
CC (P.a.) or Staphylococcus aureus (S.a.); CTP:CMP-3-deoxy-D-manno-  
CC octulosonate transferase of Escherichia coli (E.c.) or Haemophilus  
CC influenzae (H.i.); UDP-N-acetylmuramylalanyl-D-glutamate- 2,6-  
CC diaminopimelate ligase of P.a.; D-alanine:D-alanine adding enzyme of S.a.  
CC or P.a.; D-alanine-D-alanine ligase of Enterococcus faecalis (E.f.); UDP-N  
CC -acetylpuuvoylglucosamine reductase of P.a. or H.i.; UDP-N-  
CC acetylglucosamine pyrophosphorylase of E.f., H.i. or S.a.; UDP-N-  
CC acetylmuramoylalanine-D-glutamate ligase of E.f. or H.i.; DP-N-  
CC acetylmuramate:alanine ligase of E.c.; and aspartate semialdehyde  
CC dehydrogenase of H.i and UDP-N-acetylmuramoylalanyl-D-glutamate (sic) of  
CC H.i. Crystalline (I) are used to determine (by X-ray diffraction  
CC analysis) the structural coordinates of (I), and these then used to  
CC design modulators of (I), potential therapeutic agents for treating  
CC diseases caused by the specified bacteria. This sequence represents a  
CC protein of the invention.  
XX  
SQ Sequence 458 AA;

Query Match 78.0%; Score 32; DB 7; Length 458;  
Best Local Similarity 87.5%; Pred. No. 5.4e+02;  
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 LFEILAKT 9  
||| ||||  
Db 181 LFEALAKT 188

RESULT 13  
AEC10797  
ID AEC10797 standard; protein; 458 AA.  
XX  
AC AEC10797;  
XX  
DT 20-OCT-2005 (first entry)  
XX  
DE Enterococcus faecalis GLMU protein.  
XX

KW protein purification; antibacterial; antimicrobial; infection;  
KW drug screening; UDP-N-acetylglucosamine pyrophosphorylase.  
XX  
OS Enterococcus faecalis.  
XX  
PN US2005181388-A1.  
XX  
PD 18-AUG-2005.  
XX  
PF 04-OCT-2004; 2004US-00958216.  
XX  
PR 02-APR-2002; 2002US-0369511P.  
PR 04-APR-2002; 2002US-0369817P.  
PR 04-APR-2002; 2002US-0370102P.  
PR 08-APR-2002; 2002US-0370778P.  
PR 08-APR-2002; 2002US-0370792P.  
PR 08-APR-2002; 2002US-0370820P.  
PR 08-APR-2002; 2002US-0370859P.  
PR 08-APR-2002; 2002US-0370899P.  
PR 08-APR-2002; 2002US-0370915P.  
PR 09-APR-2002; 2002US-0371067P.  
PR 09-APR-2002; 2002US-0371107P.  
PR 09-APR-2002; 2002US-0371140P.  
PR 09-APR-2002; 2002US-0371185P.  
PR 31-MAY-2002; 2002US-0385089P.  
PR 31-MAY-2002; 2002US-0385426P.  
PR 04-JUN-2002; 2002US-0385751P.  
PR 05-JUN-2002; 2002US-0386018P.  
PR 05-JUN-2002; 2002US-0386367P.  
PR 05-JUN-2002; 2002US-0386548P.  
PR 05-JUN-2002; 2002US-0386553P.  
PR 05-JUN-2002; 2002US-0386566P.  
PR 05-JUN-2002; 2002US-0386577P.  
PR 06-JUN-2002; 2002US-0386283P.  
PR 06-JUN-2002; 2002US-0386390P.  
PR 06-JUN-2002; 2002US-0386430P.  
PR 06-JUN-2002; 2002US-0386601P.  
PR 06-JUN-2002; 2002US-0386826P.  
PR 06-JUN-2002; 2002US-0386869P.  
PR 31-JUL-2002; 2002US-0399972P.  
PR 01-AUG-2002; 2002US-0400348P.  
PR 05-NOV-2002; 2002US-0424053P.  
PR 06-NOV-2002; 2002US-0424380P.  
PR 06-NOV-2002; 2002US-0424395P.  
PR 08-NOV-2002; 2002US-0425086P.  
PR 08-NOV-2002; 2002US-0425200P.  
PR 24-DEC-2002; 2002US-0436243P.  
PR 24-DEC-2002; 2002US-0436288P.  
PR 24-DEC-2002; 2002US-0436345P.

PR 24-DEC-2002; 2002US-0436349P.  
 PR 26-DEC-2002; 2002US-0436566P.  
 PR 26-DEC-2002; 2002US-0436567P.  
 PR 26-DEC-2002; 2002US-0436568P.  
 PR 27-DEC-2002; 2002US-0436675P.  
 PR 27-DEC-2002; 2002US-0436708P.  
 PR 27-DEC-2002; 2002US-0436734P.  
 PR 27-DEC-2002; 2002US-0436804P.  
 PR 27-DEC-2002; 2002US-0436834P.  
 PR 27-DEC-2002; 2002US-0436842P.  
 PR 27-DEC-2002; 2002US-0436861P.  
 PR 27-DEC-2002; 2002US-0436885P.  
 PR 27-DEC-2002; 2002US-0436889P.  
 PR 27-DEC-2002; 2002US-0436893P.  
 PR 27-DEC-2002; 2002US-0436900P.  
 PR 30-DEC-2002; 2002US-0436947P.  
 PR 30-DEC-2002; 2002US-0436971P.  
 PR 30-DEC-2002; 2002US-0436987P.  
 PR 30-DEC-2002; 2002US-0437013P.  
 PR 30-DEC-2002; 2002US-0437038P.  
 PR 30-DEC-2002; 2002US-0437141P.  
 PR 31-DEC-2002; 2002US-0437281P.  
 PR 31-DEC-2002; 2002US-0437527P.  
 PR 31-DEC-2002; 2002US-0437620P.  
 PR 31-DEC-2002; 2002US-0437638P.  
 PR 02-APR-2003; 2003WO-CA000462.  
 PR 04-APR-2003; 2003WO-CA000464.  
 PR 08-APR-2003; 2003WO-CA000481.  
 PR 08-APR-2003; 2003WO-CA000485.

XX

PA (AFFI-) AFFINIUM PHARM INC.

XX

PI Edwards A, Dharamsi A, Vedadi M, Alam MZ, Arrowsmith C, Awrey DE;  
 PI Beattie B, Buzadzija K, Canadien V, Domagala M, Houston S;  
 PI Kanagarajah D, Li Q, Mansoury K, Mcdonald M, Nethery-Brokk K, Ng I;  
 PI Ouyang H, Pinder B, Richards D, Tai M, Thalakada R, Vallee F;  
 PI Virag C;

XX

DR WPI; 2005-628189/64.

DR N-PSDB; AEC10796.

XX

PT New composition comprising purified polypeptides from bacteria (e.g.  
 PT Escherichia coli), useful for diagnosing, preventing or treating  
 PT microbial infections, or in pharmacogenomic or drug screening procedures.

XX

PS Claim 57; SEQ ID NO 329; 667pp; English.

XX

CC The invention relates to a composition (I) comprising purified  
 CC polypeptides from bacteria. Also described: (1) a crystallized,

CC recombinant polypeptide comprising an amino acid sequence of (I), where  
CC the polypeptide is in crystal form; (2) a crystallized complex comprising  
CC the crystallized, recombinant polypeptide and a co-factor or a small  
CC organic molecule, where the complex is in crystal form; and (3) a host  
CC cell comprising a nucleic acid encoding a polypeptide of (I), where a  
CC culture of the host cell produces at least about 1 mg of the polypeptide  
CC per liter of culture and the polypeptide is at least about one-third  
CC soluble as measured by gel electrophoresis. The composition and methods  
CC are useful for diagnosing, preventing or treating diseases, such as  
CC microbial infections. These may also be used in pharmacogenomic or drug  
CC screening procedures. The present sequence represents a *Enterococcus*  
CC *faecalis* UDP-N-acetylglucosamine pyrophosphorylase protein sequence,  
CC which is used in an example from the present invention.

XX

SQ Sequence 458 AA;

Query Match 78.0%; Score 32; DB 10; Length 458;  
Best Local Similarity 87.5%; Pred. No. 5.4e+02;  
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 LFEILAKT 9  
||| ||||  
Db 181 LFEALAKT 188

RESULT 14

AAU35344

ID AAU35344 standard; protein; 461 AA.

XX

AC AAU35344;

XX

DT 14-FEB-2002 (first entry)

XX

DE *Enterococcus faecalis* cellular proliferation protein #631.

XX

KW Antisense; prokaryotic cellular proliferation protein; antibiotic;  
KW antibacterial; drug design.

XX

OS *Enterococcus faecalis*.

XX

PN WO200170955-A2.

XX

PD 27-SEP-2001.

XX

PF 21-MAR-2001; 2001WO-US009180.

XX

PR 21-MAR-2000; 2000US-0191078P.

PR 23-MAY-2000; 2000US-0206848P.

PR 26-MAY-2000; 2000US-0207727P.

PR 23-OCT-2000; 2000US-0242578P.  
PR 27-NOV-2000; 2000US-0253625P.  
PR 22-DEC-2000; 2000US-0257931P.  
PR 16-FEB-2001; 2001US-0269308P.  
XX  
PA (ELIT-) ELITRA PHARM INC.  
XX  
PI Haselbeck R, Ohlsen KL, Zyskind JW, Wall D, Trawick JD, Carr GJ;  
PI Yamamoto RT, Xu HH;  
XX  
DR WPI; 2001-611495/70.  
DR N-PSDB; AAS53203.  
XX  
PT New polynucleotides for the identification and development of  
PT antibiotics, comprise sequences of antisense nucleic acids.  
XX  
PS Example 3; SEQ ID NO 10937; 511pp; English.  
XX  
CC The invention relates to antisense inhibitors of genes essential to  
CC prokaryotic cellular proliferation, their use in identifying the genes,  
CC their use in the discovery of novel antibiotics, the essential genes  
CC themselves and the encoded proteins. The prokaryotes used are Escherichia  
CC coli, Staphylococcus aureus, Salmonella typhi, Klebsiella pneumoniae,  
CC Pseudomonas aeruginosa and Enterococcus faecalis. The invention is also  
CC useful for the identification of potential new targets for antibiotic  
CC development. The antisense nucleic acids can also be used to identify  
CC proteins used in proliferation, to express these proteins, and to obtain  
CC antibodies capable of binding to the expressed proteins. The proteins can  
CC be used to screen compounds in rational drug discovery programmes. The  
CC antisense nucleic acid sequence is also useful to screen for homologous  
CC nucleic acids which are required for cell proliferation in a wide variety  
CC of organisms. The present sequence represents an essential prokaryotic  
CC cellular proliferation protein. Note: The sequence data for this patent  
CC did not form part of the printed specification, but was obtained in  
CC electronic format directly from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 461 AA;

Query Match 78.0%; Score 32; DB 4; Length 461;  
Best Local Similarity 87.5%; Pred. No. 5.4e+02;  
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 LFEILAKT 9  
||| ||||  
Db 184 LFEALAKT 191

ADH86988

ID ADH86988 standard; protein; 463 AA.

XX

AC ADH86988;

XX

DT 22-APR-2004 (first entry)

XX

DE Enterococcus faecalis polypeptide #1468.

XX

KW Enterococcus faecalis infection; transcription regulatory element;  
KW antibacterial.

XX

OS Enterococcus faecalis.

XX

PN US6617156-B1.

XX

PD 09-SEP-2003.

XX

PF 13-AUG-1998; 98US-00134000.

XX

PR 15-AUG-1997; 97US-0055778P.

XX

PA (DOUC/) DOUCETTE-STAMM L A.

PA (BUSH/) BUSH D.

XX

PI Doucette-Stamm LA, Bush D;

XX

DR WPI; 2003-895394/82.

DR N-PSDB; ADH83583.

XX

PT New nucleic acid comprising a sequence encoding an Enterococcus fecalis  
PT polypeptide, useful for preparing a composition for diagnosing or  
PT treating E. fecalis infection.

XX

PS Disclosure; SEQ ID NO 4873; 193pp; English.

XX

CC The invention relates to Enterococcus faecalis polynucleotides and  
CC polypeptides. The invention also relates to a recombinant expression  
CC vector comprising a polynucleotide operably linked to a transcription  
CC regulatory element, a cell comprising a recombinant vector, a method for  
CC producing an E. faecalis polypeptide, an isolated nucleic acid comprising  
CC a sequence not given in the specification, a recombinant vector  
CC comprising the nucleic acid and a cell comprising the recombinant vector.  
CC The polynucleotides can be used to detect the presence of E. faecalis in  
CC a sample. The sequences are useful for preparing a composition for  
CC diagnosing or treating Enterococcus faecalis infection. This sequence  
CC represents an E. faecalis polypeptide of the invention.

XX

SQ Sequence 463 AA;

Query Match 78.0%; Score 32; DB 7; Length 463;  
Best Local Similarity 87.5%; Pred. No. 5.5e+02;  
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 LFEILAKT 9  
||| ||||  
Db 186 LFEALAKT 193

Search completed: June 30, 2008, 17:53:11  
Job time : 77.875 secs

SCORE 3.0